Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
HUMAN GENOME SCIENCES INC (HGSI)
|
Add to portfolio |
|
|
|
| Price: |
$10.97
| | Metrics |
| OS: |
200.0
|
M
| |
-118
|
% ROE
|
| Market cap: |
$2.19
|
B
| |
-36
|
% ROIC
|
|
Net debt:
|
$155
|
M
| |
|
|
|
EV:
|
$2.35
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($273)
|
M
| |
|
|
|
EBIT
|
($296)
|
M
| |
|
|
| EPS |
($1.80)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 | Dec-31-04 |
| Revenues | 131.0 | 157.4 | 275.7 | 48.4 | 41.9 | 209.2 | 228.7 | 219.5 |
| Revenue growth | -16.8% | -42.9% | 469.5% | 15.7% | -80.0% | -8.5% | 4.2% | 14.7% |
| Cost of goods sold | 76.1 | 45.0 | 34.0 | 0.0 | -3.7 | 238.8 | 228.7 | 235.0 |
| Gross profit | 54.9 | 112.4 | 241.7 | 48.4 | 45.5 | -29.5 | 0.0 | -15.4 |
| Gross margin | 41.9% | 71.4% | 87.7% | 100.0% | 108.8% | -14.1% | 0.0% | -7.0% |
| Research and development | 196.2 | 196.4 | 173.7 | 243.3 | 246.3 | | | |
| General and administrative | 158.8 | 106.8 | 61.1 | 60.9 | 55.9 | 53.1 | 42.1 | 35.7 |
| EBIT | -331.3 | -190.8 | 6.9 | -255.7 | -256.6 | -266.1 | -251.7 | -266.9 |
| EBIT margin | -252.9% | -121.2% | 2.5% | -528.1% | -613.2% | -127.2% | -110.0% | -121.5% |
| Pre-tax income | -381.1 | -233.2 | 4.4 | -268.9 | -284.4 | -251.2 | -239.4 | -242.9 |
| Income taxes | 0.0 | 0.0 | -1.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -381.1 | -233.2 | 5.7 | -268.9 | -284.4 | -251.2 | -239.4 | -242.9 |
| Net margin | -291.0% | -148.2% | 2.1% | -555.3% | -679.5% | -120.0% | -104.7% | -110.6% |
| |
| Diluted EPS | ($1.97) | ($1.24) | $0.04 | ($1.99) | ($2.12) | ($1.91) | ($1.83) | ($1.87) |
| Shares outstanding (diluted) | 193.7 | 187.8 | 155.1 | 135.4 | 134.3 | 131.8 | 130.8 | 130.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|